FDA Guidance Will Spur More Companion Diagnostic/Drug Trials – Nuvelo Exec
This article was originally published in The Gray Sheet
Executive Summary
Unclear regulatory pathways for molecular diagnostic tests used to predict patients' response to particular drug therapies can impede the FDA approval process, Abbott Diagnostics Regulatory Affairs Director Matthew Klamrzynski maintained